Medicare May Scale Back Coverage Restrictions For Alzheimer’s Drugs; Will It Be Enough?
Even if the final Medicare national coverage decision switches to a registry, Aduhelm access will still be too limited, patient advocates worry, prompting them to ‘move the conversation’ to Congress for relief. Prospects for a new Republican majority in the House could help.
You may also be interested in...
Medicare Registry-Based Studies For Alzheimer’s Drugs Still ‘Challenging’ Prospect – Former CMS Official
Medicare coverage with evidence development requirements for Alzheimer’s drugs that obtain traditional approvals may be more involved than they appear.
Medicare Alzheimer’s Decision Varies Evidence Mandate For Accelerated vs. Traditional Approvals
Final Medicare national coverage determination aims to set up a ‘nimble’ system to allow for broad and rapid patient access to drugs for Alzheimer’s disease following traditional approval while retaining a more restrictive approach for accelerated approvals.
A New Patient Voice In The Medicare/Alzheimer’s Drug Coverage Debate
Individuals with Down syndrome are particularly vulnerable to the disease yet would be excluded from participating in clinical trials described in the draft Medicare coverage policy for Alzheimer’s drugs.